-
Je něco špatně v tomto záznamu ?
Profile of cognitive deficits in schizophrenia and factor structure of the Czech MATRICS Consensus Cognitive Battery
O. Bezdicek, J. Michalec, L. Kališová, T. Kufa, F. Děchtěrenko, M. Chlebovcová, F. Havlík, MF. Green, KH. Nuechterlein
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- kognice MeSH
- konsensus MeSH
- lidé MeSH
- neuropsychologické testy MeSH
- psychiatrické posuzovací škály MeSH
- schizofrenie (psychologie) MeSH
- schizofrenie * komplikace diagnóza MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Česká republika MeSH
We aimed to validate the Czech version of the MATRICS Consensus Cognitive Battery (MCCB). The MCCB is a test battery designed to assess cognitive treatment effects in clinical trials of patients with schizophrenia. The valid, reliable and replicable measurement of cognition in schizophrenia is of substantial importance for such clinical trial studies. We performed a psychometric analysis of the MCCB composite and domain scores based on ROC analysis of 67 schizophrenia patients and 67 age- and education-matched healthy controls from a total sample of 220 controls. Also, we correlated MCCB variables with scales measuring psychosocial functioning (Personal and Social Performance scale; PSP). The internal consistency of all 10 tests in the MCCB battery was good (Cronbach's α = 0.85 (95% CI [0.83, 0.88])). The discriminative validity for the detection of neurocognitive dysfunction in schizophrenia based on the area under the curve of MCCB composite T-score was ≥90% (95% CI [0.85, 0.96]) and all MCCB domains showed ps < .001. The MCCB global composite and the Speed of Processing domain score significantly predicted the PSP ratings. A confirmatory factor analysis on the whole control sample (N = 220) showed an optimal fit for a 6-factor in comparison to 1-factor solution. In conclusion, we found high discriminative validity for the Czech MCCB version, similar to the differentiation of schizophrenia versus healthy control groups in the original MCCB studies. We also established the factorial validity of the MCCB and showed that the overall composite of the MCCB predicts psychosocial functioning in the patient group.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21020673
- 003
- CZ-PrNML
- 005
- 20210830102300.0
- 007
- ta
- 008
- 210728s2020 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.schres.2020.02.004 $2 doi
- 035 __
- $a (PubMed)32089475
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Bezdicek, Ondrej $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Czech Republic. Electronic address: ondrej.bezdicek@gmail.com
- 245 10
- $a Profile of cognitive deficits in schizophrenia and factor structure of the Czech MATRICS Consensus Cognitive Battery / $c O. Bezdicek, J. Michalec, L. Kališová, T. Kufa, F. Děchtěrenko, M. Chlebovcová, F. Havlík, MF. Green, KH. Nuechterlein
- 520 9_
- $a We aimed to validate the Czech version of the MATRICS Consensus Cognitive Battery (MCCB). The MCCB is a test battery designed to assess cognitive treatment effects in clinical trials of patients with schizophrenia. The valid, reliable and replicable measurement of cognition in schizophrenia is of substantial importance for such clinical trial studies. We performed a psychometric analysis of the MCCB composite and domain scores based on ROC analysis of 67 schizophrenia patients and 67 age- and education-matched healthy controls from a total sample of 220 controls. Also, we correlated MCCB variables with scales measuring psychosocial functioning (Personal and Social Performance scale; PSP). The internal consistency of all 10 tests in the MCCB battery was good (Cronbach's α = 0.85 (95% CI [0.83, 0.88])). The discriminative validity for the detection of neurocognitive dysfunction in schizophrenia based on the area under the curve of MCCB composite T-score was ≥90% (95% CI [0.85, 0.96]) and all MCCB domains showed ps < .001. The MCCB global composite and the Speed of Processing domain score significantly predicted the PSP ratings. A confirmatory factor analysis on the whole control sample (N = 220) showed an optimal fit for a 6-factor in comparison to 1-factor solution. In conclusion, we found high discriminative validity for the Czech MCCB version, similar to the differentiation of schizophrenia versus healthy control groups in the original MCCB studies. We also established the factorial validity of the MCCB and showed that the overall composite of the MCCB predicts psychosocial functioning in the patient group.
- 650 _2
- $a kognice $7 D003071
- 650 _2
- $a konsensus $7 D032921
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a neuropsychologické testy $7 D009483
- 650 _2
- $a psychiatrické posuzovací škály $7 D011569
- 650 12
- $a schizofrenie $x komplikace $x diagnóza $7 D012559
- 650 _2
- $a schizofrenie (psychologie) $7 D012565
- 651 _2
- $a Česká republika $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Michalec, Jiří $u Department of Psychiatry, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic
- 700 1_
- $a Kališová, Lucie $u Department of Psychiatry, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic
- 700 1_
- $a Kufa, Tomáš $u Department of Psychiatry, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic
- 700 1_
- $a Děchtěrenko, Filip $u The Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Chlebovcová, Miriama $u Department of Psychiatry, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic
- 700 1_
- $a Havlík, Filip $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Czech Republic
- 700 1_
- $a Green, Michael F $u Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Department of Veterans Affairs VISN 22 Mental Illness Research, Education, and Clinical Center, Los Angeles, CA, USA. Electronic address: mgreen@ucla.edu
- 700 1_
- $a Nuechterlein, Keith H $u Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Department of Psychology, University of California Los Angeles, Los Angeles, CA, USA. Electronic address: keithn@ucla.edu
- 773 0_
- $w MED00006666 $t Schizophrenia research $x 1573-2509 $g Roč. 218, č. - (2020), s. 85-92
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32089475 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830102301 $b ABA008
- 999 __
- $a ok $b bmc $g 1691281 $s 1141119
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 218 $c - $d 85-92 $e 20200220 $i 1573-2509 $m Schizophrenia research $n Schizophr Res $x MED00006666
- LZP __
- $a Pubmed-20210728
